Browse > Home / Pharmacy Industry News / Indian Stem Cell Trial To Broaden Diabetic Foot Inclusion Criteria

Indian Stem Cell Trial To Broaden Diabetic Foot Inclusion Criteria

September 17, 2009


Fortis Healthcare, one of India’s leading private hospital groups, has announced it will widen inclusion criteria for its upcoming diabetic foot clinical trial. The inquire into will use radical cells derived from peripheral blood to refreshment critical member ischemia (diabetic lower part). Current management of diabetic foot ulcers involves intensive wound prudent conduct, expose to danger reduction and prolix rehabilitation. The current treatments available for diabetic foot are both expensive and labor intensive. The close attention direction end whether stem cells can be effectively used to treat and make easy faster redemption for this condition. The trial is being sponsored by Beike Biotech India Private Company Limited.

Diabetic foot disease is the most trite serious entanglement of diabetes and be possible to lead to recurring wounds, frequently in the form of foot ulcers. The nerve damage and impaired relations circulation found in diabetics play a key role in ulcer formation. In severe cases, the affected limb must be partially or completely amputated.

While the study’s design was formally approved by the Indian Council of Medical Research (ICMR) in June 2009, the original inclusion criteria have proven prohibitively narrow, limiting subject enrollment and delaying the start of the study.

Dr. Anoop Misra, director of the trial, explained that the inclusion criteria were based on helmsman studies conducted in China. “Out of over 150 patients screened, only single in kind subject fit our original criteria.” He went on to suggest that diabetic foot ailment instructed in a clinical setting may obtain differing characteristics in India and China. Fortis notified the Indian Council of Medical Research of the neediness to revise the inclusion criteria, and it subsist able to now offer for consideration forward. The action was scheduled to start in July and to comprise a total of 36 patients, of whom 12 are to be randomly selected to receive stop cell treatment.

The trial’sitting focus is on healing diabetic pay ulcers with stem cells. If effective, the treatment should turn to account blood perfusion in the ischemic area of the fall member. This improvement will be assessed through measuring the change in transcutaneous partial pressure of oxygen (TCpO2), and will likewise connect NMR angiography of the local vessels, impost of ulcer composing, pain relief, limb salvage, and the ABI index. Diabetic foot ailment is a serious issue in India. A successful burden leave have significant implications in quest of future treatment of the condition.

“Many of our stem cell treatments to date have focused on rare and otherwise incurable conditions. This study marks an important step in verifying the applicability of root cell therapies to added commonly occurring, serious pathologies,” said Dr. Sean Hu, CEO and Chairman of Shenzhen Beike Biotechnologies Co. Ltd., regarding the implications of the study. Hu continued, “The Chinese steer trial yielded promising results that is encouraging for everyone who deals with patients affected by diabetic foot disease or related ischemic complications. As with all philosophical advancements, it is important to demonstrate that it is effective and reproducible in the broader between nations setting. The replication of this research in India self-reliance both underline the effectiveness of the treatment protocol we be obliged developed and demonstrate that it can be applied by the international therapeutical community.”

The preceding study in China produced promising results, increasing blood perfusion, markedly reducing ulceration, and raising TCpO2 levels. In more cases patients regained function in limbs that had been candidates for amputation.

Lalit Jaiswal, CEO of Beike Biotech India Private Company Limited, added, “China has been at the forefront of stem cell technology for the sake of particular years, and this study is a logical next step for the company. It is exciting that we will now be able to examine the potential of peripheral blood-derived primitive word cells to induce neovascularization,” Lalit continued, “The clinical prize of bone marrow stem cells has been known for years, and we hear about fetal and embryonic stem cells in the news every epoch. In this study, though, we are processing a sick person’s own consanguinity to isolate stem cells and then using these stem cells to come to conditions their diabetic foot ulcers and circulatory problems. When this sorrow is over we will have confirmed whether a diabetic patient’s have peripheral feelings can be used to prevail upon the growth of new blood vessels in their damaged tissue.”

The clinical endeavor is officially titled, “A Randomized, Controlled, Parallel Design, Safety and Efficacy Study of Granulocyte Colony Stimulating Factor Mobilized Autologous Peripheral Blood Mononuclear Cell Therapy in Subjects With Diabetic Limb Ischemia.” India’s Council of Medical Research approved the study after verifying that it met all associated criteria in terms of design and controls like well as following moral and safety standards.

“The large number of people who applied to enroll in this inquire into confirms that there is strong exaction for this therapy and a extremity to augment current treatment methods. However, to register plenty subjects for a successful study we have determined that we must broaden the inclusion criteria and reapply to ICMR. Now that we be under the necessity notified the ICMR we wish restart the trial in October,” said Dr. Anoop Misra.

Source: Shenzhen Beike Biotechnology Co. Ltd

Written by Samanta · Filed Under Pharmacy Industry News